Multiple STIs Could Be Detected with A Single Rapid Test
|
By LabMedica International staff writers Posted on 26 Apr 2016 |

Image: A disposable cartridge for testing for a sexually transmitted disease (Photo courtesy of Atlas Genetics).
One test that could detect four of the most common sexually transmitted infections (STIs) in 30 minutes and allow them to be rapidly treated is under development. A GBP150,000 grant has been awarded to develop the test that will detect STIs, including chlamydia and gonorrhea.
Testing kits have been sent out by the UK National Chlamydia Screening Program aimed at those aged under 25 who did not have symptoms but wished to know they are clear of the infection. Their samples were then sent away for testing and those who tested positive for Chlamydia were offered the opportunity to trial the new technology.
Chlamydia is the UK’s most common STI with about 100,000 cases diagnosed each year and people under 25 years old are most at risk. If untreated, it can have serious long-term health consequences, including infertility in women. In some areas, one in five people never get treatment for their infection and others wait a long time before coming back to a clinic.
The test is being developed by scientists at St George’s, University of London (UK) and Atlas Genetics (Trowbridge, UK). The STI multiplex combines tests for four major nucleic acid targets, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, without the need for microscopy. The test is run on the Atlas Genetics’ io system which is a fully automated solution, requiring minimal hands-on time. Following the addition of an unprocessed patient specimen on to the io Cartridge, the Cartridge is then inserted in to the io Reader.
Tariq Sadiq MD, chief investigator at St. George’s, leads the eSTI2 Consortium which has developed a new smartphone app which allows patients to access an electronic clinic, the eSexual Health Clinic, to get rapid online treatment for chlamydia infection once they were diagnosed. Using a secure National Health System (NHS) log in, the app included an online medical consultation, leading to an electronic prescription for antibiotics, which patients could collect at a high street pharmacy. The app also enabled the patients’ sexual partners to get treatment quickly and easily in the same way. A clinical helpline is available for patients who need advice or support.
Eventually the eSexual Health Clinic will link to a hand held diagnostic device for STIs is also being developed by the scientists. This will mean that a urine or swab sample from patients would not have to be sent away for analysis, but can be analyzed at home so patients would receive their results within half an hour and then get their care online without ever needing to see a doctor face to face or attend a clinic.
Related Links:
St George’s, University of London
Atlas Genetics
Testing kits have been sent out by the UK National Chlamydia Screening Program aimed at those aged under 25 who did not have symptoms but wished to know they are clear of the infection. Their samples were then sent away for testing and those who tested positive for Chlamydia were offered the opportunity to trial the new technology.
Chlamydia is the UK’s most common STI with about 100,000 cases diagnosed each year and people under 25 years old are most at risk. If untreated, it can have serious long-term health consequences, including infertility in women. In some areas, one in five people never get treatment for their infection and others wait a long time before coming back to a clinic.
The test is being developed by scientists at St George’s, University of London (UK) and Atlas Genetics (Trowbridge, UK). The STI multiplex combines tests for four major nucleic acid targets, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, without the need for microscopy. The test is run on the Atlas Genetics’ io system which is a fully automated solution, requiring minimal hands-on time. Following the addition of an unprocessed patient specimen on to the io Cartridge, the Cartridge is then inserted in to the io Reader.
Tariq Sadiq MD, chief investigator at St. George’s, leads the eSTI2 Consortium which has developed a new smartphone app which allows patients to access an electronic clinic, the eSexual Health Clinic, to get rapid online treatment for chlamydia infection once they were diagnosed. Using a secure National Health System (NHS) log in, the app included an online medical consultation, leading to an electronic prescription for antibiotics, which patients could collect at a high street pharmacy. The app also enabled the patients’ sexual partners to get treatment quickly and easily in the same way. A clinical helpline is available for patients who need advice or support.
Eventually the eSexual Health Clinic will link to a hand held diagnostic device for STIs is also being developed by the scientists. This will mean that a urine or swab sample from patients would not have to be sent away for analysis, but can be analyzed at home so patients would receive their results within half an hour and then get their care online without ever needing to see a doctor face to face or attend a clinic.
Related Links:
St George’s, University of London
Atlas Genetics
Latest Technology News
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Channels
Clinical Chemistry
view channel
Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
Counterfeit and substandard medicines remain a serious global health threat, with World Health Organization estimates suggesting that 10.5% of medicines in low- and middle-income countries are either fake... Read more
Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
Acute recreational drug toxicity is a frequent reason for emergency department visits, yet clinicians rarely have access to confirmatory toxicology results in real time. Instead, treatment decisions are... Read moreMolecular Diagnostics
view channel
New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids
Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more
AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy
Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more
AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







